Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06263088 | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | recruiting | N/A | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06687603 | Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms | recruiting | N/A | 800 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07255001 | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life(PanFit) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06557733 | An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06732388 | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | recruiting | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06789198 | Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA(FusionVAC22_02) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303) | recruiting | Phase 3 | 900 | Revolution Medicines, Inc.INDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT07615374 | Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer | recruiting | N/A | 36 | Jilin UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT05630794 | Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05753748 | Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia(SURVENT) | recruiting | N/A | 680 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05845450 | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | recruiting | Phase 2 | 197 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05850130 | Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients(ACUPOX) | recruiting | N/A | 182 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | recruiting | Phase 2 | 60 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06651580 | Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | recruiting | — | 1,600 | M.D. Anderson Cancer CenterOTHER | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT07081360 | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer | recruiting | Phase 3 | 262 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07132541 | Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)(NBCA) | recruiting | Phase 1 | 30 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07148830 | Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.(TMpE) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | recruiting | Phase 3 | 570 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection(BRAVE) | recruiting | — | 1,000 | Imperial College LondonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04864054 | GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC(ARYA-3) | recruiting | Phase 1 / Phase 2 | 60 | Eureka Therapeutics Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06524973 | Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers | recruiting | N/A | 136 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06563947 | Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy | recruiting | Phase 2 | 30 | Xu Yong, MDOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07161869 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)(POELH-III) | recruiting | — | 250 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | recruiting | N/A | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | recruiting | Phase 2 | 29 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811752 | Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study(HCC) | recruiting | — | 1,000 | Mansoura UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY) | recruiting | Phase 2 / Phase 3 | 300 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06175845 | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma(ACTICCA-2) | recruiting | N/A | 130 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials